Comment from Mobius Therapeutics, LLC (Arnall Golden Gregory LLP)

Summary: Mobius Therapeutics, LLC, represented by legal counsel Arnall Golden Gregory LLP, argues that mitomycin should not be included on the Bulk Substances List for compounding. They contend that mitomycin is highly toxic, unstable in solution, and poses significant safety and efficacy risks when compounded by outsourcing facilities, especially since an FDA-approved product (Mitosol) is already available.